Intrarosa

Prasterone, the active ingredient in Intrarosa, is an androgen presented as a 6.5 mg vaginal insert for vaginal use. It is indicated for the treatment of dyspareunia associated with vulvar and vaginal atrophy in postmenopausal women, improving vaginal tissue health and comfort.

GNH USA supplies Intrarosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this specialty therapy for qualified prescribers. The company adheres to stringent quality standards and offers comprehensive logistics support for global distribution.

Intrarosa is used in the management of vulvar and vaginal atrophy, a condition related to estrogen deficiency in postmenopausal women. - Dyspareunia associated with vulvar and vaginal atrophy: reduces pain during intercourse and improves vaginal lubrication. - Vulvar atrophy: restores tissue elasticity and reduces dryness. - Vaginal atrophy: promotes epithelial maturation and increases moisture.

Adverse reactions reported with vaginal inserts of prasterone are generally mild and localized.

Common Side Effects: - Vaginal discharge or spotting. - Local irritation or itching. - Mild abdominal discomfort. - Headache.

Serious or Rare Side Effects: - Significant vaginal bleeding. - Allergic reaction such as rash or swelling. - Systemic hormonal effects, including unexpected breast tenderness or changes in menstrual pattern.

Before prescribing Intrarosa, consider the following precautions: - Pregnancy: safety not established; avoid use in pregnant women. - Breastfeeding: unknown safety; weigh potential risks and benefits. - Hormone‑sensitive conditions: use with caution in patients with estrogen‑dependent tumors. - Allergy: discontinue if hypersensitivity to prasterone or excipients occurs. - Local irritation: monitor for severe irritation or infection. - Store at room temperature: keep in original packaging, protect from moisture and heat.

Prasterone may interact with other hormonal or vaginal products.

Major Interactions (Avoid): - Systemic estrogen therapy: may increase overall hormone exposure. - Other androgenic agents: additive hormonal effects. - Concurrent vaginal antifungal or antibiotic preparations: may alter local conversion.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors or inducers: could affect metabolism of prasterone metabolites. - Hormonal contraceptives: monitor for potential efficacy changes. - Other local vaginal products: assess for irritation or reduced effectiveness.